[go: up one dir, main page]

AR015976A1 - Composiciones que contienen agonistas de h2 de histamina para el tratamiento del ojo seco y el uso de las mismas en la manufactura de un medicamento - Google Patents

Composiciones que contienen agonistas de h2 de histamina para el tratamiento del ojo seco y el uso de las mismas en la manufactura de un medicamento

Info

Publication number
AR015976A1
AR015976A1 ARP980105251A ARP980105251A AR015976A1 AR 015976 A1 AR015976 A1 AR 015976A1 AR P980105251 A ARP980105251 A AR P980105251A AR P980105251 A ARP980105251 A AR P980105251A AR 015976 A1 AR015976 A1 AR 015976A1
Authority
AR
Argentina
Prior art keywords
manufacture
dry eye
agonists
same
compositions containing
Prior art date
Application number
ARP980105251A
Other languages
English (en)
Original Assignee
Alcon Mfg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Mfg Ltd filed Critical Alcon Mfg Ltd
Publication of AR015976A1 publication Critical patent/AR015976A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion para el tratamiento del ojo seco en humanos, que comprende una cantidad farmacéuticamente efectiva de uno o más agonista(s) de H2 dehistamina tales como dimaprit, anthamine e impromidine, en un portador farmacéuticamente aceptable; yel uso de la misma para la manufactura de unmedicamento.
ARP980105251A 1997-10-21 1998-10-21 Composiciones que contienen agonistas de h2 de histamina para el tratamiento del ojo seco y el uso de las mismas en la manufactura de un medicamento AR015976A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6290697P 1997-10-21 1997-10-21

Publications (1)

Publication Number Publication Date
AR015976A1 true AR015976A1 (es) 2001-05-30

Family

ID=22045617

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105251A AR015976A1 (es) 1997-10-21 1998-10-21 Composiciones que contienen agonistas de h2 de histamina para el tratamiento del ojo seco y el uso de las mismas en la manufactura de un medicamento

Country Status (5)

Country Link
US (1) US6274160B1 (es)
AR (1) AR015976A1 (es)
AU (1) AU1104799A (es)
WO (1) WO1999020265A1 (es)
ZA (1) ZA989513B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011034551A2 (en) 2009-09-15 2011-03-24 Qlt Inc. Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
KR20180043846A (ko) 2010-04-19 2018-04-30 노벨리언 테라퓨틱스 인코포레이티드 내인성 레티노이드 결핍과 연관된 시각 장애의 치료 또는 완화를 위한 치료 요법 및 방법
CA2865935C (en) 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4315024A (en) * 1980-08-08 1982-02-09 Cooper Laboratories, Inc. Compositions and method for treating red eye
US4744980A (en) 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ES2084722T3 (es) 1990-05-29 1996-05-16 Boston Ocular Res Composicion para tratamiento del ojo seco.
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5294433A (en) 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
BR9203277A (pt) 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses

Also Published As

Publication number Publication date
ZA989513B (en) 1999-04-21
WO1999020265A1 (en) 1999-04-29
US6274160B1 (en) 2001-08-14
AU1104799A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
CL2008001920A1 (es) Composicion farmaceutica que comprende un inhibidor de la pde 2, un agonista del receptor selectivo e2 y un portador; y uso en el tratamiento de fractura y/o defecto oseo (div. sol. 3179-04).
YU38802A (sh) Nova kompozicija i njena upotreba
MD960330A (ro) Compuşi nepeptidilici, compoziţie farmaceutică pe baza acestora, metodă de tratament
AU2855399A (en) Vascularization inhibitors
ES2081531T3 (es) Composiciones farmaceuticas que contienen rifaximina para el tratamiento de infecciones vaginales.
MY129356A (en) Electrospun pharmaceutical compositions
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
CR6592A (es) Compuestos para el tratamiento de la isquemia
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
HUP0103567A3 (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists, process for their preparation and pharmaceutical compositions containing the same
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
AR017222A1 (es) Procedimiento de utilizacion de un agente que inhibe el desarrollo de p.ovale, en la preparacion de medicamentos
YU13301A (sh) Muskarinski agonisti i antagonisti
SV2008002856A (es) 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas
SE9802937D0 (sv) Novel compounds
IL139318A (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
AR024232A1 (es) Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion
AR015976A1 (es) Composiciones que contienen agonistas de h2 de histamina para el tratamiento del ojo seco y el uso de las mismas en la manufactura de un medicamento
HRP20000781B1 (hr) Šumeći pripravci
ES2193007T1 (es) Formulacion farmaceutica estable que comprende la modificacion ii de torsemida.
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
ES2185698T3 (es) Composicion de tratamiento anti-acne de la piel.
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.